Quick Answer
MindMaze Therapeutics Holding SA reported R&D Expense of $1.33 million for fiscal year 2023.
MindMaze Therapeutics Holding SA R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $1.33M | -89.3% |
| 2022 | $12.39M | -34.9% |
| 2021 | $19.02M | — |
- MindMaze Therapeutics Holding SA showed a decrease of -89.3% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2023 period, MindMaze Therapeutics Holding SA’s r&d expense has declined by 93.0% (from $19.02 million to $1.33 million).
- The most recent figure is from MindMaze Therapeutics Holding SA’s fiscal year 2023 report (Form 20-F), filed with the SEC on April 30, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: